Related Experiment Video
Updated: Mar 12, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Racial Disparities in the Diagnosis and Management Between Secondary Care Ethnic Minority and White British Patients
Amalie Newman-Booth1,2, Emma Fairhurst2, Dipesh H Vasant1,2
1University of Manchester, Manchester, UK.
Background:
Irritable bowel syndrome (IBS) is a highly prevalent disorder of gut-brain interaction best understood within a biopsychosocial framework. Recent studies in other healthcare systems have suggested racial disparities in the management of IBS.
Aims:
We aimed to investigate racial disparities in the diagnosis and management of IBS including adherence to national guidelines between White British and Ethnic minority patients with IBS in a UK secondary care setting.
Methods:
Consecutive Ethnic minority patients (N = 68) with a coded secondary care diagnosis of IBS at a gastroenterology department in a large UK teaching hospital were identified from electronic health records. Data on diagnostic pathways and access to treatments and adherence to national guidelines were compared statistically with an equal number of age and gender matched white British controls (N = 68).
Results:
Compared to age and gender matched White British controls, Ethnic Minority patients saw more clinicians (p = 0.012) and required more outpatient appointments to make an IBS diagnosis (p = 0.007). There were disparities identified in the approach to treatment, with ethnic minority patients less likely to be recommended second-line pharmacological treatment (p = 0.004) and Brain-Gut Behavioral Therapies (p = 0.005) compared to their White British counterparts. Across both groups, adherence to national guidelines in the diagnostic approach and treatment for IBS was low, with most patients not being recommended second-line medical, dietary, or behavioral treatment for their IBS.
Conclusions:
These data suggest that the management of IBS in secondary care in the UK has not kept pace with advances in evidence-based treatments and updated guidelines. Moreover, racial disparities, whether influenced by clinicians or patients, were seen between the two ethnic groups regarding the diagnosis and management of IBS. Further studies are necessary to determine the barriers contributing to these disparities, to influence future interventions and clinical training to address them.
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...